Tecentriq (Atezolizumab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The tecentriq (atezolizumab) market size has grown rapidly in recent years. It will grow from $4.36 million in 2025 to $4.89 million in 2026 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to limitations of chemotherapy, breakthrough immunotherapy approvals, rising cancer incidence, clinical success of pd-l1 inhibitors, hospital-centered oncology care.

The tecentriq (atezolizumab) market size is expected to see rapid growth in the next few years. It will grow to $7.65 million in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to growth in oncology clinical trials, expansion of biomarker-based treatment, increased cancer screening rates, rising healthcare investment in oncology, improved survival outcomes. Major trends in the forecast period include rising adoption of immune checkpoint inhibitors, expansion of indications across multiple cancers, increased use of combination immunotherapy, growth in precision oncology approaches, shift toward personalized cancer treatment.

The rising prevalence of cancer is expected to drive the growth of the Tecentriq (atezolizumab) market in the coming years. The increasing number of cancer cases is attributed to factors such as an aging population, improved detection methods, lifestyle changes, environmental exposures, and better survival rates, all of which contribute to more people being diagnosed and living with cancer. Tecentriq (atezolizumab) plays a crucial role in cancer management by harnessing the immune system to target cancer cells. It blocks PD-L1, a protein that allows tumors to evade immune detection, enabling T-cells to recognize and destroy cancer cells more effectively. For instance, in January 2024, the American Cancer Society, a US-based nonprofit organization, reported that cancer cases rose to 2,001,140, compared to 1,958,310 in 2023, reflecting a 2.19% increase. Consequently, the rising prevalence of cancer is driving the Tecentriq (atezolizumab) market.

A key trend in the Tecentriq (atezolizumab) market is the development of innovative formulations, such as intravenous and subcutaneous preparations, to ensure precise dosing, rapid systemic absorption, and consistent therapeutic levels. The intravenous formulation delivers the monoclonal antibody efficiently via infusion for systemic cancer treatment. For example, in September 2024, Genentech Inc., a US-based biotechnology company, received U.S. Food and Drug Administration approval for atezolizumab and hyaluronidase-tqjs for subcutaneous injection. Tecentriq became the first subcutaneous anti-PD-L1 therapy approved in the U.S., offering a faster administration time of approximately 7 minutes compared to the 30-60 minutes required for intravenous infusion, while maintaining comparable efficacy in drug exposure and overall response rates, as demonstrated in the IMscin001 trial. It is indicated for multiple adult cancers, including NSCLC, SCLC, melanoma, hepatocellular carcinoma, and alveolar soft part sarcoma.

In October 2024, Lonza Group AG, a Switzerland-based pharmaceutical, biotechnology, and nutrition company, acquired Roche’s Vacaville large-scale biologics manufacturing facility for $1.2 billion. This acquisition strengthens Lonza’s West Coast commercial manufacturing presence near San Francisco’s biotech hub, complementing its East Coast site in Portsmouth, New Hampshire, and its global network across Europe and the Asia Pacific. The expansion enhances Lonza’s ability to manufacture late-stage clinical and commercial products and support the production of new molecules approaching commercialization. Roche Holding AG, also based in Switzerland, is a leading manufacturer of pharmaceuticals and biologics, including Tecentriq (atezolizumab).

Major companies operating in the tecentriq (atezolizumab) market are Roche Holding AG, Chugai Pharmaceutical Co. Ltd.

North America was the largest region in the tecentriq (atezolizumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tecentriq (atezolizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tecentriq (atezolizumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the tecentriq market by increasing costs related to imported biologic substances, formulation reagents, and infusion delivery systems. These increases have affected oncology treatment budgets, particularly in hospital and specialty clinic settings. Regions such as asia-pacific and latin america are more exposed due to reliance on imported immunotherapies. At the same time, tariffs have supported local biologics production initiatives, strengthened oncology supply resilience, and encouraged long-term investment in cancer treatment infrastructure.

The tecentriq (atezolizumab) market research report is one of a series of new reports that provides tecentriq (atezolizumab) market statistics, including tecentriq (atezolizumab) industry global market size, regional shares, competitors with a tecentriq (atezolizumab) market share, detailed tecentriq (atezolizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the tecentriq (atezolizumab) industry. This tecentriq (atezolizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tecentriq (Atezolizumab) is a monoclonal antibody immunotherapy that belongs to the class of immune checkpoint inhibitors. It specifically targets programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 or B7.1 receptors on T-cells. This inhibition reactivates the immune system, allowing T-cells to recognize and destroy cancer cells.

The main types of Tecentriq (Atezolizumab) include PD-L1 inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, immunomodulators, and others. The PD-L1 inhibitor form of Tecentriq is a monoclonal antibody that blocks PD-L1, preventing it from suppressing the immune response against cancer cells. It is indicated for lung cancer, bladder cancer, melanoma, Hodgkin’s lymphoma, head and neck cancer, and other malignancies. Tecentriq is distributed through hospital pharmacies, retail pharmacies, and online pharmacies and is used by a range of end users, including hospitals, homecare services, and specialty clinics.

The tecentriq (atezolizumab) market consists of sales of biosimilars, immuno-oncology pipeline drugs, supportive oncology medications and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.